Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 18 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 9 institutions in 3 countries.
Carine S F MarquesPostgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil.
Nathalia S BarretoPostgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil.
Simone S C de OliveiraDepartament of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University l Rio de Janeiro, 21941-918 Rio de Janeiro, RJ, Brazil.
André L S SantosDepartament of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University l Rio de Janeiro, 21941-918 Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-0821-8592
Marta H BranquinhaDepartament of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University l Rio de Janeiro, 21941-918 Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-9752-8148
Damião P de SousaDepartment of Pharmaceutical Sciences, Federal University of Paraíba, 58051-900 Paraíba, Brazil.ORCID 0000-0002-7180-4896
Mayara CastroDepartment of Pharmaceutical Sciences, Federal University of Paraíba, 58051-900 Paraíba, Brazil.ORCID 0000-0001-5967-9554
Luciana N AndradeDepartment of Medicine, Federal University of Sergipe, CEP 49400-000 Lagarto, Sergipe, Brazil.
Matheus M PereiraCICECO-Aveiro Institute of Materials, Departamento f Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0003-3524-6900
Classius F da SilvaDepartment of Exact Sciences and Earth, Federal University of São Paulo (UNIFESP), 09972-270 Diadema CEP, Brazil.
Marco V ChaudDepartment of Technological and Environmental Processes, Sorocaba University (UNISO), Rod. Raposo Tavares, Km 92.5, 18023-000 Sorocaba, Brazil.ORCID 0000-0003-3618-8415
Sona JainPostgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil.
Alini T FricksPostgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil.ORCID 0000-0001-9888-952X
Eliana B SoutoDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciênciasda Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.ORCID 0000-0002-9737-6017
Patricia SeverinoPostgraduation in Biotechnology Program, Industrial and Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil.ORCID 0000-0001-6527-6612
Instituto de Tecnologia e Pesquisa · BRUniversidade Federal do Rio de Janeiro · BRUniversidade Federal da Paraíba · BRBrigham and Women's Hospital · USUniversidade de Sorocaba · BRUniversidade Federal de São Paulo · BRUniversidade Federal de Sergipe · BRUniversity of Aveiro · PTUniversity of Coimbra · PT
Funding
Banco do Nordeste grant FUNDECI/2016.0015Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPq 301964/2019-0 Chamada 06/2019, and Chamada CNPq nº 01/2019Coordenação Aperfeiçoamento de Pessoal de Nivel Superior (CAPES) and Fundação de Ámparo à Pesquisa do Estado de Sergipe (FAPITEC) PROCESSO: 88887.159533/2017-00Portuguese Science and Technology Foundation (FCT) UIDB/04469/2020 (strategic fund)
6 · The paper itself
Abstract
Isopentyl caffeate (ICaf) is a bioactive ester widely distributed in nature. Our patented work has shown promising results of this molecule against Leishmania. However, ICaf shows poor solubility, which limits its usage in clinical settings. In this work, we have proposed the development of an inclusion complex of ICaf in β-cyclodextrin (β-CD), with the aim to improve the drug solubility, and thus, its bioavailability. The inclusion complex (ICaf:β-CD) was developed applying three distinct methods, i.e., physical mixture (PM), kneading (KN) or co-evaporation (CO) in different molar proportions (0.25:1, 1:1 and 2:1). Characterization of the complexes was carried out by thermal analysis, Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM) and molecular docking. The ICaf:β-CD complex in a molar ratio of 1:1 obtained by CO showed the best complexation and, therefore, was selected for further analysis. Solubility assay showed a marked improvement in the ICaf:β-CD (CO, 1:1) solubility profile when compared to the pure ICaf compound. Cell proliferation assay using ICaf:β-CD complex showed an IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
β-Cyclodextrin/Isopentyl Caffeate Inclusion Complex: Synthesis, Characterization and Antileishmanial Activity. · full record | Socratic